2024
DOI: 10.1002/cac2.12577
|View full text |Cite
|
Sign up to set email alerts
|

Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study

Jiayu Wang,
Yunjiang Liu,
Qingyuan Zhang
et al.

Abstract: BackgroundDisitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast, gastric, and ovarian cancers with different levels of HER2 expression. In this pooled analysis, we report the safety and efficacy of DV in patients with HER2‐overexpression and HER2‐low advanced breast cancer (ABC).… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
references
References 35 publications
0
0
0
Order By: Relevance